fashion -WSS

fashion

author：knowledge 2025-09-29 21:20:57 - browse：48

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Alnylam reports growth in sales of rare disease treatments

WSS

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Alnylam reports growth in sales of rare disease treatments

FDA scientists endorse Pfizer/BioNTech Covid

Driven by the pandemic, applicants flood public health schools

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

23andMe had bad news about my health. I wish a person had delivered it

Why Congress must ban federal programs from using QALYs

Hollywood unions extend contract negotiations for actors

The a glaring gap in research on serious mental illness and primary care

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Heart attack and stroke risk calculators need revising

Tocagen's brain cancer gene therapy trial continues. Investors worry

State Dept. review finds Biden bears some blame for Afghanistan failures

Heart disease in astronauts blamed on cosmic radiation

explore

EF3 tornado rips through North Carolina amid extreme weather nationwide

Biotech startup Celsius cuts 75% of staff ahead of first trial start

FDA approves Sage Therapeutics’ rapid

DeSantis talks Trump, trans issues and 'what wokeness is'

Personalized medicine goes far beyond genetics

Indian pharmaceutical industry in denial over drug

explore

leisure time

Wikipedia

explore